Washington University School of Medicine: Multiple Myeloma trials

The registry lists 39 Multiple Myeloma studies with Washington University School of Medicine as lead sponsor. 7 are open to participants now and 11 have results posted.

Early Phase 1 5Phase 1 14Phase 2 16No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersRecruitingNCT07226934Not applicable
• Selinexor Maintenance Post CAR-T Cell Therapy for Multiple MyelomaRecruitingNCT07200102Phase 1
• Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)RecruitingNCT07200089Phase 1
• Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal FunctionRecruitingNCT06623630Phase 1
• Measurable Residual Disease-Guided Post-Transplant Elranatamab MaintenanceRecruitingNCT06483100Phase 2
• Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)RecruitingNCT06340646Not applicable
• Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple MyelomaRecruitingNCT06185751Phase 1
• Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)CompletedNCT04682405Phase 2Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple MyelomaActive, not recruitingNCT02253316Phase 2Results posted
• A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous TransplantationTerminatedNCT02112045Phase 2Results posted
• Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin LymphomaCompletedNCT02098109Phase 2Results posted
• Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell TransplantationTerminatedNCT01653418Phase 2Results posted
• Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01246063Phase 1/2Results posted
• Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling DonorsCompletedNCT01158118Phase 2Results posted
• A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple MyelomaCompletedNCT00429949Phase 2Results posted
• Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological MalignanciesCompletedNCT00241358Phase 1/2Results posted
• PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple MyelomaTerminatedNCT00240162Phase 2Results posted
• Implementing a Randomized Control Trial to Test the Expanded Web-based Decision AidActive, not recruitingNCT06910670Not applicable
• 64Cu-LLP2A for Imaging Hematologic MalignanciesTerminatedNCT06636175Early Phase 1
• A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF MobilizationCompletedNCT06547112Phase 1
• Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell TransplantActive, not recruitingNCT06523699Phase 1
• Providing Cancer Care Closer to Home for Patients With Multiple MyelomaTerminatedNCT05971056Not applicable
• Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplantWithdrawnNCT05820763Phase 2
• Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY DiseaseTerminatedNCT04912427Phase 1
• Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple MyelomaWithdrawnNCT04150692Phase 2
• Isatuximab, Bendamustine, and Prednisone in Refractory Multiple MyelomaTerminatedNCT04083898Phase 1
• 64Cu-LLP2A for Imaging Multiple MyelomaTerminatedNCT03804424Early Phase 1
• Lenalidomide Adherence in Older AdultsTerminatedNCT03779555
• Allogeneic Stem Cell Transplantation for Patients With Multiple MyelomaWithdrawnNCT02447055Early Phase 1
• Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT02220608Phase 1
• Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02117115Early Phase 1
• Study of Hypotensive Hematopoietic Malignancy Patients' USCOM ReadingsCompletedNCT01755000Not applicable
• Geriatric Assessments in Senior Adults With Multiple MyelomaCompletedNCT01746030
• Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple MyelomaTerminatedNCT01537861Early Phase 1
• Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed DiseaseCompletedNCT00871702Phase 1
• A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple MyelomaCompletedNCT00545519Phase 1
• A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00241371Phase 2
• Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous TherapyTerminatedNCT00006220Phase 1/2